August 1, 2016

Medical Use of Marijuana Program
Department of Public Health
99 Chauncy Street, 11th Floor
Boston, Massachusetts 02111

Re: Update to Chief Operating Officer for MassMedicum Corp. (Application 1 of 2)

To Whom It May Concern:

Please be advised that this correspondence is intended to notify the Department of Public Health ("DPH") that Jeremy Bromberg will be replacing Dr. James T. Kurnick as the COO of MassMedicum Corp. ("MassMedicum").

In support of this change, please find enclosed the following documents:

1. Updated responses to MassMedicum’s Management and Operations Profile as they pertain to all sections regarding the COO;
2. Section C: Character and Competency Form for Jeremy Bromberg;
3. Section D: Employment and Education form for Jeremy Bromberg; and
4. A sealed envelope containing background check forms for Jeremy Bromberg.

Dr. Kurnick will still be serving as CEO and CFO of MassMedicum. MassMedicum will promptly inform the DPH of any future changes to the Executive Management Team.

Thank you for your attention to this matter.

Very Truly Yours,

[Signature]

Philip C. Silverman, Esq.

PCS/tc

RECEIVED

AUG 01 2016

MA Dept. of Public Health
99 Chauncy Street
Boston, MA 02111
SECTION D. EXPERIENCE

16. Attach an Employment and Education form (use template provided) for each of the following individuals: The Corporation's Chief Executive Officer, Chief Operations Officer, Chief Financial Officer, individual/entity responsible for marijuana for medical use cultivation operations, and individual/entity responsible for the RMD security plan and security operations.

17. Describe the experience, and length of experience, of the Corporation's Chief Executive Officer, Chief Operations Officer, and Chief Financial Officer with running a non-profit organization or business.

James T. Kurnick, M.D. (CEO, COO and CFO) brings over 35 years of non-profit and business experience in the healthcare industry to MassMedicum's Executive Management Team. Since 1980, he has been on the medical staff at a premier teaching hospital and on the faculty of a leading medical school in Boston, MA. As the Associate Chief of Pathology for Research at his hospital, he served on the Executive Committee that helped to manage a department with over 500 employees, covering all of the tissue pathology, clinical laboratories and blood bank services. As Director of the Pathology Research Laboratory, he oversaw the development of a new 20,000 square foot research laboratory, coordinating with architects, builders and administrators to create a state-of-the-art facility. His research has been supported by grants from the NIH and private foundations and has led to several patents as well as playing a key role in the development of "Entyvio," a successful therapy for inflammatory bowel diseases.

In 1999, Dr. Kurnick co-founded CytoCure, LLC, a biotechnology company that created a novel platform technology to develop anti-cancer drugs that will make therapeutic cancer vaccines more effective. He has led CytoCure through private financing and NIH grants, while supervising operations as the company. CytoCure has identified numerous compounds with potential therapeutic uses leading to filing and obtaining multiple patents.

Dr. Kurnick subsequently co-founded TriBiotica, LLC, a biotechnology company dedicated to developing breakthrough technology for targeting cancer and other disease-causing cells. TriBiotica has developed proprietary technologies that will allow unique targeting of tumor cells and related diagnostic assays.

Since 2013, Dr. Kurnick has served as Chief Executive Officer, President, Chief Medical Officer and Treasurer of MassMedicum, Inc., a Massachusetts non-profit corporation that obtained on of the fifteen initial provisional licenses for a RMD approved by the Massachusetts DPH.

Jeremy Bromberg (COO) has over three decades of experience running businesses and is the Founder and Principal of Bromberg, LLC, where he serves as a business advisor working with owners of small and mid-size professional service firms to improve their companies’ growth trajectories. Prior to starting Bromberg LLC in 2008, Jeremy was the Managing Director at Eidetics, a leading pharmaceutical market research firm. During his 14-year tenure, the company averaged annual revenue growth of 20% and employee retention over 90%. Before his work at Eidetics, Jeremy worked at Teradyne, where he managed the New Product Development function for the Board Test division, and he designed and implemented a process for product development.

Information on this page has been reviewed by the applicant, and where provided by the applicant, is accurate and complete, as indicated by the initials of the authorized signatory here: JTK
18. Describe the experience, and length of experience, of the Corporation’s Chief Executive Officer, Chief Operations Officer, and Chief Financial Officer with providing health care services.

James T. Kurnick, M.D. (CEO, COO and CFO) is a licensed physician with over 40 years of experience providing health care services. Since 1980, he has been on the staff at a leading Boston hospital and medical school. He has taken leadership roles at the hospital and medical school and oversees two biotechnology companies and MassMedicum, a provisionally licensed RMD.

As a service and research pathologist, Dr. Kurnick is intimately familiar with both laboratory and patient-management issues and has extensive experience in documenting and managing patient specimens and HIPAA protocols to assure patient privacy.

Dr. Kurnick’s research in tumor immunology paved the way for his pioneering study of Tumor-Infiltrating Lymphocytes. His group performed one of the world’s first transfers of a patient’s own tumor-specific T-Lymphocytes to treat advanced lung cancers and melanomas. This therapy required the coordination of a staff of laboratory technicians with clinical staff to assure strict adherence to protocols and product quality. The protocols he developed carefully monitored and documented each aspect of the patient response, from adverse events to therapeutic efficacy. In addition, his group produced a unique monoclonal antibody that was subsequently developed into an approved drug for treatment of inflammatory bowel diseases (“Entyvio”).

As an Associate Professor at a premier medical school, he led a team of more than 100 physician-educators to coordinate a medical school course that constituted approximately 25% of the first-year curriculum, including introductory pathology, immunology and microbiology.

As noted in Question #17, Dr. Kurnick co-founded and oversees operations at two biotechnology companies, CytoCure, LLC and TriBiotica, LLC that have created potable breakthrough technologies for cancer treatments. In addition, Dr. Kurnick leads MassMedicum, Inc., the recipient of one of the initial 15 provisional licenses to operate a RMD in Massachusetts.

Although he does not have any direct experience providing health care services, Jeremy Bromberg (COO) ran all aspects of the day-to-day business operations of a leading pharmaceutical market research firm in his 14 years at Eidecis. During this time, the company averaged annual revenue growth of 20% and employee retention over 90%. In addition to his experience leading teams and projects, Jeremy’s hands-on responsibilities included new product development, resource management, performance tracking and analysis, and organizational structure in a pharmaceutical setting that makes him an ideal counterpart to Dr. Kurnick in the day-to-day operations of a dispensary.

Information on this page has been reviewed by the applicant, and where provided by the applicant, is accurate and complete, as indicated by the initials of the authorized signatory here: JTK
19. Describe the experience, and length of experience, of the Corporation’s Chief Executive Officer, Chief Operations Officer, and Chief Financial Officer with providing services for marijuana for medical purposes.

James T. Kurnick, M.D. (CEO, COO and CFO) has immersed himself in the cannabis industry since Massachusetts approved medical marijuana in November 2012. Aided by an elite team of industry, legal, security, financial, engineering, architectural, and construction experts, Dr. Kurnick has developed considerable industry knowledge and experience providing services for marijuana for medical purposes, resulting in the receipt of one of the first fifteen provisional licenses to operate a RMD in Massachusetts.

Dr. Kurnick has focused on refining how a medical marijuana non-profit organization can help patients achieve better outcomes through producing and dispensing the highest-grade medical marijuana therapeutics in a professional setting. To that effect, the MassMedicum team has consulted with leaders in the medical marijuana markets in Colorado and California, met with patients who benefit from medical marijuana, and made fact-finding visits to states with longstanding medical marijuana experience.

Additionally, Dr. Kurnick, an experienced medical researcher, has investigated the current status of medical marijuana products and the potential of cannabinoids to treat various diseases and symptoms. He has recruited medicinal chemists with expertise in extraction of medical products from natural sources, including production of nano-particle cannabinoids. Nano-particles are measured in billionths of a meter and have shown potential as effective treatments for cancer and arteriosclerosis. MassMedicum intends to license patented technology from its collaboration with medicinal chemists that will enable MassMedicum to produce and dispense nano-particle cannabis products, including transdermal patches and oral medications that offer the potential for improved absorption, half-life and bioavailability.

Jeremy Bromberg (COO) has no previous experience providing services for marijuana for medical purposes.

The MassMedicum team has worked closely with cultivators, architects, and engineers to design a 33,000 square foot production facility, located in Holbrook, MA. This state-of-the-art facility will incorporate innovative design features to help avoid the mold and insect problems that have plagued many New England growers. Water purification systems and proprietary soil mixes will assure that plants will be free of toxic chemicals and contaminants. MassMedicum has received approvals for its operations from both the Town of Holbrook and the City of Taunton. A full set of plans have been submitted to the Town of Holbrook, and the company expects to begin sales at its RMD in 2016.
SECTION D. EMPLOYMENT AND EDUCATION FORM

This Employment and Education form must be completed and signed by each of the following individuals: The Corporation's Chief Executive Officer, Chief Operations Officer, Chief Financial Officer, individual/entity responsible for marijuana for medical use cultivation operations, and individual/entity responsible for the RMD security plan and security operations. Submit one Employment and Education form for each of the above individuals when submitting a Management and Operations Profile to the Department of Public Health.

Name
Jeremy Bromberg

Residential Address

Title (at applicant non-profit corporation)
Chief Operating Officer

Name of Applicant Non-Profit Corporation
MassMedicum Corp.

Highest Education Attained – Institution, Degree, and Year
Kenyon College, B.A., 1980
Past 10 Years of Employment by Employer, Title and Time Period. List chronologically, beginning with most recent employment. Add more forms if space is needed for additional employment history entries.

<table>
<thead>
<tr>
<th>Employer</th>
<th>Title</th>
<th>Time Period</th>
</tr>
</thead>
<tbody>
<tr>
<td>Bromberg, LLC</td>
<td>Principal</td>
<td>Feb 2008 - current</td>
</tr>
<tr>
<td>Eidetics</td>
<td>Managing Director, Operations</td>
<td>June 1994 - Jan 2008</td>
</tr>
</tbody>
</table>

Signed under the pains and penalties of perjury, I agree and attest that all information included in this form is complete and accurate.

Signature of the Individual

July 22, 2016
Date Signed